Background/Aims: Ketamine inhibits the proliferation of neural stem cells (NSCs) and disturbs normal neurogenesis. Dexmedetomidine provides neuroprotection against volatile anesthetic-induced neuroapoptosis and cognitive impairment in the developing brain. Whether it may protect NSCs from ketamine-induced injury remains unknown. In this study, we investigated the protective effects of dexmedetomidine on ketamine-exposed NSCs and explored the mechanisms potentially involved. Methods: Primary NSC cultures were characterized using immunofluorescence. Cell viability was determined using a Cell Counting Kit 8 assay. Proliferation and apoptosis were assessed with BrdU incorporation and TUNEL assays, respectively. Protein levels of cleaved caspase-3, phosphorylated protein kinase B (p-Akt), and glycogen synthase kinase-3β (p-GSK-3β) were quantified using western blotting. Results: Ketamine significantly decreased NSC viability and proliferation and increased their apoptosis. Dexmedetomidine increased NSC proliferation and decreased their apoptosis in a dose-dependent manner. Furthermore, dexmedetomidine pretreatment notably augmented the viability and proliferation of ketamine-exposed NSCs and reduced their apoptosis. Moreover, dexmedetomidine lessened caspase-3 activation and increased p-Akt and p-GSK-3β levels in NSCs exposed to ketamine. The protective effects of dexmedetomidine on ketamine-exposed NSCs could be partly reversed by the PI3K inhibitor LY294002. Conclusions: Collectively, these findings indicate that dexmedetomidine may protect NSCs from ketamine-induced injury via the PI3K/Akt/GSK-3β signaling pathway.
Introduction
Ketamine is commonly used in pediatric anesthesia [1] . Recent studies have shown that ketamine inhibits the proliferation of neural stem cells (NSCs), disturbing normal neurogenesis [2, 3] , and causes neurodegeneration and neuroapoptosis in the developing brain, ultimately leading to long-term neurocognitive dysfunctions [4] [5] [6] [7] [8] . These findings have obligated medical workers to reevaluate the use of ketamine in pediatric anesthetic practice and to search for possible protective measures.
The α 2 -adrenoceptor subtype is widely expressed during brain development [9] . It mediates the neurotrophic effects of norepinephrine and dendrite growth in cortical neurons during fetal cortical development [10, 11] . Dexmedetomidine, an α 2 -adrenoceptor agonist, is an effective auxiliary medicine in clinical anesthesia and intensive care due to its anxiolytic, sedative, and analgesic activity. Dexmedetomidine can prevent neurodegeneration from cerebral ischemia and spinal injury [12, 13] . Several recent studies have shown that dexmedetomidine has protective effects on isoflurane-and sevoflurane-induced neurodegeneration in the developing rat brain [14] [15] [16] . In pediatric practice, anesthesiologists preferentially select the combination of ketamine and dexmedetomidine to reduce the adverse effects of ketamine [17] [18] [19] . However, it remains unknown whether dexmedetomidine can attenuate ketamine-induced injury in NSCs.
The phosphatidylinositol 3-kinase (PI3K) and Akt pathway is a major cell signaling pathway that mediates signal transduction during normal cell physiological activities [20] . Activation of the PI3K/Akt signaling pathway has been reported to protect the brain from ischemia-reperfusion injury and ketamine-induced cortical neuronal apoptosis [3, [20] [21] [22] . Interestingly, the PI3K/Akt/GSK-3β signaling pathway is also involved in the protective effects of dexmedetomidine on isoflurane-induced neurotoxicity in the neonatal rat brain [23] . It is unclear if the PI3K/Akt/GSK-3β signaling pathway mediates the protective effects of dexmedetomidine on ketamine-exposed NSCs. In this study, we investigated the protective effects of dexmedetomidine on ketamine-induced injury of NSCs and proposed that PI3K/ Akt/GSK-3β signaling might be involved in this protection.
Materials and Methods

Animals
Timed-pregnant Sprague-Dawley rats were provided by the Experimental Animal Center of Xi'an Jiaotong University (Certificate No. 22-9601018). All animal studies complied with the regulations of the Animal Care and Use Committee of Xi'an Jiaotong University and the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23). Pregnant rats were housed in a 12-h light/dark cycle with free access to food and water.
Cell culture NSC isolation procedures were conducted as described in our previously reported methods [24] . Briefly, 8 to 12 rat fetuses at embryonic day 18 (E18) were obtained from timed-pregnant rats under sterile conditions. All of the anterior cortices were extracted from the fetuses, cut into pieces, and enzymatically digested with accutase (Sigma-Aldrich, St. Louis, MO, USA) for 5 min at 37°C. The cell pellets were resuspended in DMEM/F12 (GIBCO, L.A., CA, USA) proliferation medium with 20 ng/ml of epidermal growth factor (EGF; GIBCO) and basic fibroblast growth factor (bFGF, GIBCO) and 2% N 2 , 1% B27, and 100 U/ml penicillin and streptomycin (GIBCO). The cell suspensions were seeded in 24-well plates precoated with poly-L-lysine (Sigma-Aldrich) or in 96-well plates and cultured at 37°C in an atmosphere of 5% CO 2 . Half of the culture medium was replaced every 3 days. After 5-7 days in culture, the neurospheres were dissociated into a cell suspension by incubation with accutase (Sigma-Aldrich) for 5 min. The cells were seeded at a density of 2 × 10 5 cells/ml. For differentiation assessment, the cells from passage 1 of neurospheres were seeded at a density of 1 × 10 4 cells/ml in 24-well plates and cultured in basal medium with 10% fetal bovine serum (FBS) for 4 h. Afterward, the medium was replaced with complete medium to allow differentiation for 7 days.
Immunofluorescence and nuclear staining
The cultured cells and their proliferation potency were characterized and tested by immunofluorescence analysis. The cells were treated with 10 μg/l of BrdU for the last 4 h of the drug treatments and fixed with 4% paraformaldehyde for 30 min at room temperature. After washing, the cells were permeabilized with 0.3% Triton X-100 for 10 min and treated with blocking buffer (5% goat serum) for 1 h prior to incubation with the primary antibodies overnight at 4°C. The primary antibodies used were as follows: mouse monoclonal anti-nestin antibody (1:500; Millipore, Billerica, MA, USA), rabbit polyclonal anti-glial fibrillary acidic protein (GFAP) antibody (1:1000; Sigma-Aldrich), and mouse monoclonal anti-β-tubulin III antibody (1:1000; Sigma-Aldrich) for NSC identification; rabbit polyclonal anti-N-methyl-D-aspartate receptor 1 (NMDAR1) antibody (1:100; Abcam, Cambridge, MA, USA) and goat polyclonal anti-α-2A adrenergic receptor antibody (1:100; Abcam) to examine the expressions of NMDAR1 and α-2A adrenergic receptor in NSCs, respectively; and rat monoclonal anti-BrdU (1:1000; Abcam) to detect proliferating cells. Cells were washed and incubated with secondary antibodies (fluorescein isothiocyanate [FITC] or tetramethylrhodamine isothiocyanate [TRITC]-conjugated IgG) for 2 h followed by incubation with 4′,6′-diamidino-2′-phenylindole (DAPI; 1:1000; Abcam) for 10 min at room temperature. The slides were rinsed with PBS and imaged using a laser confocal microscope (TSC SP2, Leica, Mannheim, Germany). At least three independent experiments were conducted per assay.
TUNEL fluorescent assay
To detect NSC apoptosis in the different treatment groups, cells were labeled with TUNEL. The procedure was conducted in accordance with the instructions of the In Situ Cell Death Detection Kit (Roche, Mannheim, Germany). The slides were protected from light during the experiment and nuclei were counterstained with DAPI. TUNEL-positive cells were analyzed as for the immunofluorescent staining.
Measurement of cell viability
Cell viability was tested by a Cell Counting Kit 8 (CCK8) assay (Dojindo Molecular Technologies, Gaithersburg, MD, USA) according to the manufacturer's protocol. Briefly, each well was incubated with 10 μl of 5 mg/ml CCK8 solution at 37°C for the last 4 h of drug treatments. The CCK8 solution was then removed and 200 μl of dimethyl sulfoxide was added to dissolve the formazan. The optical density was detected with a plate reader at 450 nm.
Western blot analysis
Western blot analysis was used to detect caspase-3 cleavage and phosphorylation of Akt and GSK-3β as described previously [25] . Equal amounts of cell lysates were used for the analyses. Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. Membranes were blocked for 2 h at room temperature and incubated with primary antibodies overnight at 4°C. The following primary antibodies were used: mouse monoclonal anti-β-actin antibody (as a control, internal standard, 1:10, 000; Cell Signaling Technology Inc., Beverly, MA, USA), rabbit polyclonal anti-caspase-3 antibody (1:1000; Cell Signaling Technology) to detect full-length caspase-3 (35-40 kDa) and caspase-3 fragments (17-20 kDa), rabbit polyclonal anti-phosphorylated Akt antibody (p-Akt, 1:1000; Cell Signaling Technology), rabbit polyclonal anti-phosphorylated GSK-3β antibody (p-GSK-3β, 1:1000; Cell Signaling Technology), mouse polyclonal anti-Akt antibody (Akt, 1:1000; Cell Signaling Technology), and mouse polyclonal anti-GSK-3β antibody (GSK-3β, 1:1000; Cell Signaling Technology). After being thoroughly /DAPI + cells were counted in a randomized blinded fashion. Five to seven sections from each well were randomly selected for quantification. For the TU-NEL staining, only densely labeled cells were considered positive [26] . 
Results
Identification of NSCs
Nestin, a cytoskeletal intermediate filament protein, is a marker for NSCs and neural progenitor cells. To characterize the cultured cells, we first performed immunofluorescent staining with nestin. Nestin-positive cells comprised approximately 95-98% of all neurosphere-forming cells (Fig. 1A) . Because NSCs have the ability to differentiate into neurons and astrocytes, we seeded the cells in complete medium with FBS to allow their differentiation for 7 days and observed that cultured cells expressed β-tubulin III, a specific marker for neurons (Fig. 1B, arrowhead) , and GFAP, a specific marker for astrocytes (Fig. 1B, arrow) . Thus, most of the cells in this study were NSCs. To verify the expressions of NMDAR and α 2A ad- (Fig. 1D, arrow) .
Toxic effects of ketamine on NSCs
We used proliferation, apoptosis, and viability assays to evaluate the toxic effects of ketamine on NSCs. Ketamine exposure (100 μM, 24 h) decreased the percentage of BrdU-positive cells (43% vs. 62.9% in the control group, n = 18 per group, p < 0.01, Student's t test) ( Fig. 2A and Fig. 2B , compare the black and white bars), indicating that ketamine (100 μM, 24 h) might inhibit NSC proliferation. Ketamine treatment also increased the percentage of TUNEL-positive cells in NSCs (3.0% vs. 2.2% in the control group, n = 13 per group, p < 0.01, Student's t test) ( Fig. 2A and Fig. 2C , compare the black and white bars), suggesting that ketamine can induce NSC apoptosis. Moreover, ketamine exposure (100 μM, 24 h) significantly decreased cell viability as assessed by measuring the cell concentration (optical density: 0.365 vs. 1.18 in the control group, n = 6 per group, p < 0.01, Student's t test) (Fig. 4A , compare the black and white bars). 
The NSCs were also subjected to western blot analysis at the end of the treatments. Ketamine exposure (100 μM, 24 h) induced a visible increase in cleaved caspase-3 (caspase-3 fragment) compared with the control group (Fig. 4E, compare lanes 3 and 1) . Quantification of the ratio of the caspase-3 fragment to the full-length caspase-3 (FL-caspase-3) further supported this notion (299% in ketamine-treated NSCs vs. 100% in control cells, n = 3 per group, p < 0.05, oneway ANOVA) (Fig. 4B, compare the black and white bars) . In summary, these data suggest that ketamine treatment may decrease NSC proliferation and induce apoptosis, resulting in reduced cell viability.
Effects of dexmedetomidine on NSCs
To determine the optimal dose of dexmedetomidine, we first tested the effects of different concentrations of dexmedetomidine (0.1 μM, 1.0 μM, 10 μM, and 20 μM) on NSC proliferation and apoptosis using immunofluorescence. Quantification of the images illustrated that dexmedetomidine dose-dependently increased the percentage of BrdU-positive cells (65.0%, 78.0%, 77.8%, and 76.2%, respectively, vs. 62.9% in the control group; n = 12 per group, p < 0.01, oneway ANOVA) and decreased the percentage of TUNEL-positive cells (1.9%, 1.8%, 1.1%, and 1.1%, respectively, vs. 2.2% in control group; n = 13 per group, p < 0.01, one-way ANOVA) ( Fig. 2B and Fig. 2C , compare the gray and white bars). Dexmedetomidine treatment did not affect cell viability as assessed by cell concentration (optical density: 1.09 vs. 1.18 of the control group, p > 0.05, Student's t test) (Fig. 4A , compare the gray and white bars) or caspase-3 activation in NSCs (76% vs. 100% in the control group, n = 3 per group, p > 0.05, one-way ANOVA) (Fig. 4B and Fig. 4E,   Fig. 4 . The PI3K/Akt/GSK-3β pathway is involved in the protective effects of dexmedetomidine on ketamine-exposed neural stem cells. The cells were treated with 100 μM ketamine or 20 μM dexmedetomidine in the absence or presence of LY294002. C, D, K, DK, and LDK represent control, dexmedetomidine, ketamine, dexmedetomidine plus ketamine, and dexmedetomidine plus ketamine plus LY294002, respectively. (A) Effects of the different treatments on NSC viability (n = 6 per group). (B) Effects of the different treatments on caspase-3 cleavage (activation) (n = 3 per group). Caspase-3 activation is expressed as the amount of cleaved caspase-3 (caspase-3 fragment) relative to full-length caspase-3 (FL-caspase-3) and normalized to control. (C) Effects of the different treatments on Akt activation (n = 3 per group). Akt activation is expressed as the amount of phosphorylated Akt relative to total Akt and normalized to control. (D) Effects of the different treatments on GSK-3β inactivation (n = 3 per group). GSK-3β inactivation is expressed as the amount of phosphorylated GSK-3β relative to total GSK-3β and normalized to control. Equal amounts of protein extracts were analyzed by western blot. The optical densities of the target bands were normalized to β-actin. Data are shown as the mean ± SEM. *p<0.05, **p<0.01 vs. control; Δp<0.05, ΔΔp<0.01 vs. DK. 
Dexmedetomidine protects NSCs from ketamine-induced toxicity
We next assessed the effect of pretreatment with dexmedetomidine on ketamine-exposed NSCs. Dexmedetomidine pretreatment dose-dependently increased the percentage of BrdU-positive cells (39.6%, 53.9%, 56.5%, and 60.6% in the 0.1 μM, 1.0 μM, 10 μM, and 20 μM dexmedetomidine plus ketamine groups, respectively, vs. 39.5% in the ketamine group; n = 15 per group, p < 0.01, one-way ANOVA) ( Fig. 2A and Fig. 3A ) and cell viability (optical density: 0.89 vs. 0.36 in the control group, n = 6 per group, p < 0.01, one-way ANOVA) (Fig. 4A , compare the hatched and black bars). Moreover, dexmedetomidine pretreatment of ketamine-exposed NSCs decreased the percentage of TUNEL-positive cells (2.4%, 2.0%, 1.4%, and 1.3%, respectively, vs. 3.0% in the ketamine group, n = 12 per group, p < 0.01, one-way ANOVA) ( Fig. 2A and Fig. 3B ) and caspase-3 activation (140% vs. 299% in ketamine-treated NSCs, n = 3 per group, p < 0.05, one-way ANOVA) (Fig. 4B and Fig. 4E , compare the hatched and black bars). These results suggest that dexmedetomidine pretreatment may alleviate the adverse effects caused by ketamine exposure.
The PI3K/Akt/GSK-3β pathway is involved in the protective effects of dexmedetomidine on ketamine-injured NSCs
We then examined whether the PI3K/Akt/GSK-3β pathway mediated the protective effects of dexmedetomidine on ketamine-injured NSCs. We incubated NSCs with the PI3K inhibitor LY294002 (20 μM, 2 h) prior to dexmedetomidine pretreatment (20 μM, 30 min) and ketamine exposure (100 μM, 24 h). Quantification of western blotting results revealed that ketamine exposure resulted in lower p-Akt and p-GSK-3β levels in NSCs compared with the control group (27% vs. 100%, 28% vs. 100%, respectively; n = 3 per group, p < 0.05, one-way ANOVA) (Fig. 4C and Fig.  4D , compare the black and white bars, Fig. 4E, compare lanes 3 and 1) ; this decrease was partially restored by dexmedetomidine pretreatment to approximately 80% and 66%, respectively ( Fig.  4C and Fig. 4D , compare the hatched, black, and white bars, Fig. 4E, compare lanes 4, 3, and 1) . Furthermore, the PI3K inhibitor LY294002 reversed the protective effects of dexmedetomidine, causing an approximate 75% decrease in Akt phosphorylation and an approximately 80% decrease in GSK-3β phosphorylation (Fig. 4C, compare the grid and hatched bars, Fig. 4E , compare lanes 5 and 4). Likewise, LY294002 attenuated the effects of dexmedetomidine on the cell proliferation, apoptosis, and viability of ketamine-exposed NSCs (Fig. 3, black bar, Fig. 4A , compare the grid, hatched, and black bars). Collectively, these data show that dexmedetomidine may attenuate the toxic effects of ketamine on NSCs via the PI3K/Akt/GSK-3β signaling pathway.
Discussion
This study demonstrated that dexmedetomidine pretreatment attenuated ketamineinduced changes in cell viability, proliferation, and apoptosis and reversed the ketamineinduced reduction in Akt and GSK-3β phosphorylation in NSCs. In addition, the PI3K inhibitor LY294002 blocked the protective effects of dexmedetomidine on the ketamine-induced changes. These results suggest that dexmedetomidine may protect NSCs from ketamine-induced injury via the PI3K/Akt/GSK-3β pathway.
NSCs can proliferate and differentiate into neurons and glial cells and are thus critical for normal neurogenesis and gliogenesis during brain development [27] . The developing brain experiences a critical period called the brain growth spurt, which begins in humans in the last third trimester of pregnancy and lasts approximately 2 years after birth. However, in rodents, the brain growth spurt starts at the end of pregnancy and extends for the first 21 postnatal days [28] . Therefore, we investigated the effects of ketamine on NSCs obtained from embryonic day 18 rat anterior cortices. Recent studies have shown that ketamine alters the proliferation and differentiation of NSCs [29] . However, the effects of ketamine on NSCs were unclear.
Previous studies have found both dose-and time-dependent neurotoxic effects of ketamine. Prolonged exposure (24-48 h) and high concentrations (>10 μM) of ketamine caused deleterious effects, unlike shorter exposure times or lower doses [1, 30] . The concentration threshold to induce neuroapoptosis was not precisely defined in these studies but was somewhere in the 10 to 50 μM range. However, lower doses had to be administered continuously for at least 48 h to cause harmful effects. Having considered both the dose and duration, we exposed NSCs to 100 μM ketamine for 24 h to establish a ketamine injury model; this dosage was also based on the clinically relevant dose of ketamine. In the present study, we showed that ketamine decreased NSC viability and proliferation and increased apoptosis, which is consistent with previous studies [2, 31] .
NMDA receptor, a glutamate receptor subtype, plays an important role in brain development [32] . Activation of NMDA receptors can induce apoptosis in neurons [33] . It is also evident that NSCs can respond directly to manipulations caused by NMDA receptor antagonists, indicating that functional NMDA receptor is expressed on NSCs [34, 35] . In the present study, we showed that NSCs expressed NMDA receptors. Moreover, both in vivo and in vitro studies have reported that NMDA receptor is involved in the modulation of NSC activation and proliferation ( [36] [37] [38] [39] , reviewed in [40] ). As an antagonist of noncompetitive NMDA receptor, ketamine induces neuroapoptosis via a compensatory upregulation of NMDA receptor that leads to NMDA receptor dysfunction, which results in calcium overload and production of reactive oxygen species [1, 30] . NMDA receptor activation also induces PI3K/Akt signaling [41] , which contributes to NMDA-mediated neuroprotection [42] . Recently, it has been reported that activation of PI3K/Akt/GSK-3β signaling had a protective effect on ketamine-induced neuroapoptosis [21, [43] [44] [45] . Moreover, Liu et al. reported that lithium, an inhibitor of GSK-3β, could attenuate ketamine-induced neuroapoptosis [46] . Interestingly, lithium carbonate is an important therapeutic drug for psychosis while abuse of ketamine may induce psychosis [47] . All of these findings suggest that the toxic effect of ketamine is at least partly mediated via the PI3K/Akt/GSK-3β pathway. Even though the underlying mechanism remains unclear, it is certainly worth further investigation. Elucidation of this mechanism may lead to new methods for the prevention and/or treatment of anesthetic-induced neurotoxicity. In the present study, we observed a significant decrease in p-Akt and p-GSK-3β levels in ketamine-injured NSCs. These findings suggest that the PI3K/Akt/GSK-3β pathway may be involved in the neurotoxic effects of ketamine.
In contrast to ketamine, dexmedetomidine has neuroprotective effects [12, 13, [48] [49] [50] , especially on anesthetic(isoflurane and sevoflurane)-induced neurodegeneration and neuroapoptosis in the developing rat brain [15, 16, 51, 52] . However, there are only a few studies of the effects of dexmedetomidine on NSCs in vitro. Our study demonstrated the potential protective effects of 20 μM dexmedetomidine on NSCs exposed to ketamine. We showed that dexmedetomidine treatment increased the proliferation of NSCs and inhibited their apoptosis in a dose-dependent manner. The effect was observed at 0.1 μM (a clinically relevant concentration) [53, 54] and was most pronounced at 20 μM. Although some patients, especially pediatric patients, have higher requirements and better tolerance for dexmedetomidine (up to 10 times of the clinical concentration) [55, 56] , it is currently unlikely to be applied at such a high concentration (20 μM) in the clinic. Importantly, dexmedetomidine at the concentration used in this study did not significantly affect NSC viability, as shown in a CCK-8 assay, which is based on dehydrogenase activity. The discrepancy in the results between cell viability and proliferation assays could be because the increase in cell number was insufficient to cause a significant increase in dehydrogenase activity in viable cells. Furthermore, we found that dexmedetomidine pretreatment reversed the ketamine-induced decrease in NSC viability and proliferation and the increase in NSC apoptosis, indicating that dexmedetomidine protected NSCs from ketamine-induced injury. These findings suggest that, even at a higher dose than that used in the clinic, dexmedetomidine does not injure NSCs, which provides a basis for the combination use of dexmedetomidine and ketamine in pediatric anesthesia.
Adult hippocampal NSCs cultured in vitro express all α 2 -adrenoceptor subtypes [57] . From 60 to 93 days after conception (E60-93) in macaque monkey fetuses, the ventricular and sub-Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry ventricular zones, where NSCs are mainly located, display high densities of α 2 -adrenergic receptors. These high densities of α 2 -adrenergic receptors remain near the ventricular surface long after all cortical neurons have been generated [58] . Furthermore, stimulation of α 2 -adrenergic receptors increases nestin-positive cells in the mouse cortex [59] , inhibits hippocampal neural precursor cell activity, and decreases hippocampal neurogenesis [60] . Our study found that NSCs harvested from embryonic rats and grown in vitro expressed α 2A -adrenoceptor. As an α 2 -adrenoceptor agonist, the neuroprotective effects of dexmedetomidine in the developing brain have been investigated in many studies and have included mechanisms such as inhibition of calcium entry, scavenging of glutamate, activation of ERK1/2 via imidazoline receptors, activation of the Ras-Raf-pERK pathway via α 2 -adrenoceptor, reduction in NMDA receptor activation, and modulation of brain-derived neurotrophic factor expression [12, [61] [62] [63] [64] . In addition, recent research has shown that the PI3K/Akt/GSK-3β signaling pathway is also involved in the protective effects of dexmedetomidine [23, 65] . As the mechanism underlying the protective effects of dexmedetomidine on ketamine-induced neurotoxicity remains unclear, our working hypothesis is that dexmedetomidine protects ketamine-injured NSCs by activating the PI3K/Akt/GSK-3β signaling pathway. In the present study, dexmedetomidine pretreatment reversed the ketamine-induced decrease in p-Akt and p-GSK-3β levels in NSCs, and this effect was blocked by the PI3K inhibitor LY294002. These results indicate that the PI3K/Akt/GSK-3β signaling pathway mediates the protective effects of dexmedetomidine on ketamine-induced neurotoxicity. Interestingly, Li et al. reported that the PI3K/Akt pathway participates in the dexmedetomidine-mediated protection against isoflurane-induced neuroapoptosis [23] . However, the upstream mechanisms of dexmedetomidine modulation of the PI3K/Akt/GSK-3β pathway need to be studied further.
In conclusion, dexmedetomidine pretreatment protects against ketamine-induced injury in NSCs by activating the PI3K/Akt/GSK-3β pathway. These findings provide a basis for the combination use of ketamine and dexmedetomidine in pediatric anesthesia. Before its application in clinics, the safety and efficacy of the ketamine and dexmedetomidine combination needs to be tested in animal experiments. Moreover, the effects of dexmedetomidine on the developing brain and long-term neurocognitive functions require in vivo studies. The mechanisms underlying the protective effects of dexmedetomidine on ketamine-induced neurotoxicity require further experimental and clinical investigation to address these important questions.
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